{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:46:18Z","timestamp":1787240778959,"version":"build-2736575974"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The deregulation of BCL2 family proteins plays a crucial role in leukemia development. Therefore, pharmacological inhibition of this family of proteins is becoming a prevalent treatment method. However, due to the emergence of primary and acquired resistance, efficacy is compromised in clinical or preclinical settings. We developed a drug sensitivity prediction model utilizing a deep tabular learning algorithm for the assessment of venetoclax sensitivity in T-cell acute lymphoblastic leukemia (T-ALL) patient samples. Through analysis of predicted venetoclax-sensitive and resistant samples, PLK1 was identified as a cooperating partner for the BCL2-mediated antiapoptotic program. This finding was substantiated by additional data obtained through phosphoproteomics and high-throughput kinase screening. Concurrent treatment using venetoclax with PLK1-specific inhibitors and PLK1 knockdown demonstrated a greater therapeutic effect on T-ALL cell lines, patient-derived xenografts, and engrafted mice compared with using each treatment separately. Mechanistically, the attenuation of PLK1 enhanced BCL2 inhibitor sensitivity through upregulation of BCL2L13 and PMAIP1 expression. Collectively, these findings underscore the dependency of T-ALL on PLK1 and postulate a plausible regulatory mechanism.<\/jats:p>","DOI":"10.1038\/s41408-023-00914-7","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:01:51Z","timestamp":1694044911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia"],"prefix":"10.1038","volume":"13","author":[{"given":"Kinjal","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Nasimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0422-2343","authenticated-orcid":false,"given":"Mehreen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Al Ashiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linn","family":"Denison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9518-2457","authenticated-orcid":false,"given":"Wondossen","family":"Sime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Bendak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Kolosenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Siino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0710-9792","authenticated-orcid":false,"given":"Fredrik","family":"Levander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Palm-Apergi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Massoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0719-5336","authenticated-orcid":false,"given":"Julhash U.","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"914_CR1","volume":"1","author":"W Zhang","year":"2017","unstructured":"Zhang W, Chien J, Yong J, Kuang R. Network-based machine learning and graph theory algorithms for precision oncology. NPJ Precis Oncol. 2017;1:25.","journal-title":"NPJ Precis Oncol"},{"key":"914_CR2","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1016\/j.csbj.2021.07.003","volume":"19","author":"R Rafique","year":"2021","unstructured":"Rafique R, Islam SMR, Kazi JU. Machine learning in the prediction of cancer therapy. Comput Struct Biotechnol J. 2021;19:4003\u201317.","journal-title":"Comput Struct Biotechnol J"},{"key":"914_CR3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature14539","volume":"521","author":"Y LeCun","year":"2015","unstructured":"LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521:436\u201344.","journal-title":"Nature"},{"key":"914_CR4","volume":"10","author":"F Cheng","year":"2019","unstructured":"Cheng F, Kovacs IA, Barabasi AL. Network-based prediction of drug combinations. Nat Commun. 2019;10:1197.","journal-title":"Nat Commun"},{"key":"914_CR5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41563-019-0338-z","volume":"18","author":"S Ekins","year":"2019","unstructured":"Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, et al. Exploiting machine learning for end-to-end drug discovery and development. Nat Mater. 2019;18:435\u201341.","journal-title":"Nat Mater"},{"key":"914_CR6","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1016\/j.csbj.2021.06.030","volume":"19","author":"M Picard","year":"2021","unstructured":"Picard M, Scott-Boyer MP, Bodein A, Perin O, Droit A. Integration strategies of multi-omics data for machine learning analysis. Comput Struct Biotechnol J. 2021;19:3735\u201346.","journal-title":"Comput Struct Biotechnol J"},{"key":"914_CR7","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/nbt.2877","volume":"32","author":"JC Costello","year":"2014","unstructured":"Costello JC, Heiser LM, Georgii E, Gonen M, Menden MP, Wang NJ, et al. A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol. 2014;32:1202\u201312.","journal-title":"Nat Biotechnol"},{"key":"914_CR8","first-page":"6679","volume":"35","author":"S\u00d6 Arik","year":"2021","unstructured":"Arik S\u00d6, Pfister T. TabNet: attentive interpretable tabular learning. Proc AAAI Conf Artif Intell. 2021;35:6679\u201387.","journal-title":"Proc AAAI Conf Artif Intell"},{"key":"914_CR9","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524\u201339.","journal-title":"Haematologica"},{"key":"914_CR10","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.3390\/ijms18091904","volume":"18","author":"D Bongiovanni","year":"2017","unstructured":"Bongiovanni D, Saccomani V, Piovan E. Aberrant signaling pathways in T-Cell acute lymphoblastic leukemia. Int J Mol Sci. 2017;18:1904.","journal-title":"Int J Mol Sci"},{"key":"914_CR11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","volume":"13","author":"B Samra","year":"2020","unstructured":"Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020;13:70.","journal-title":"J Hematol Oncol"},{"key":"914_CR12","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","volume":"2016","author":"EA Raetz","year":"2016","unstructured":"Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Progr. 2016;2016:580\u20138.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"914_CR13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11899-019-00501-3","volume":"14","author":"CM McMahon","year":"2019","unstructured":"McMahon CM, Luger SM. Relapsed T cell all: current approaches and new directions. Curr Hematol Malig Rep. 2019;14:83\u201393.","journal-title":"Curr Hematol Malig Rep"},{"key":"914_CR14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/bmt.2016.194","volume":"52","author":"JE Brammer","year":"2017","unstructured":"Brammer JE, Saliba RM, Jorgensen JL, Ledesma C, Gaballa S, Poon M, et al. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transpl. 2017;52:20\u201327.","journal-title":"Bone Marrow Transpl"},{"key":"914_CR15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49\u201363.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"914_CR16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4049\/jimmunol.151.1.83","volume":"151","author":"J Gratiot-Deans","year":"1993","unstructured":"Gratiot-Deans J, Ding L, Turka LA, Nunez G. bcl-2 proto-oncogene expression during human T cell development. evidence for biphasic regulation. J Immunol. 1993;151:83\u201391.","journal-title":"J Immunol"},{"key":"914_CR17","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.4049\/jimmunol.151.5.2546","volume":"151","author":"DJ Veis","year":"1993","unstructured":"Veis DJ, Sentman CL, Bach EA, Korsmeyer SJ. Expression of the Bcl-2 protein in murine and human thymocytes and in peripheral T lymphocytes. J Immunol. 1993;151:2546\u201354.","journal-title":"J Immunol"},{"key":"914_CR18","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4:1074\u201387.","journal-title":"Cancer Discov"},{"key":"914_CR19","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","volume":"124","author":"S Peirs","year":"2014","unstructured":"Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124:3738\u201347.","journal-title":"Blood"},{"key":"914_CR20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"914_CR21","first-page":"456","volume":"10","author":"LE Robertson","year":"1996","unstructured":"Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996;10:456\u20139.","journal-title":"Leukemia"},{"key":"914_CR22","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-15-1191","volume":"22","author":"M Klanova","year":"2016","unstructured":"Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, et al. Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large b-cell lymphoma. Clin Cancer Res. 2016;22:1138\u201349.","journal-title":"Clin Cancer Res"},{"key":"914_CR23","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362\u201375.","journal-title":"Cancer Discov"},{"key":"914_CR24","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","volume":"78","author":"M Rahmani","year":"2018","unstructured":"Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, et al. Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells. Cancer Res. 2018;78:3075\u201386.","journal-title":"Cancer Res"},{"key":"914_CR25","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","volume":"15","author":"EA Punnoose","year":"2016","unstructured":"Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15:1132\u201344.","journal-title":"Mol Cancer Ther"},{"key":"914_CR26","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","volume":"22","author":"X Niu","year":"2016","unstructured":"Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G, et al. Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells. Clin Cancer Res. 2016;22:4440\u201351.","journal-title":"Clin Cancer Res"},{"key":"914_CR27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3389\/fcell.2020.00354","volume":"8","author":"AK Sharma","year":"2020","unstructured":"Sharma AK, Roberts RL, Benson RD Jr., Pierce JL, Yu K, Hamrick MW, et al. The senolytic drug navitoclax (ABT-263) causes trabecular bone loss and impaired osteoprogenitor function in aged mice. Front Cell Dev Biol. 2020;8:354.","journal-title":"Front Cell Dev Biol"},{"key":"914_CR28","doi-asserted-by":"crossref","unstructured":"Bohler S, Afreen S, Fernandez-Orth J, Demmerath EM, Molnar C, Wu Y et al. Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis, Haematologica. 2021;106:3136\u201348.","DOI":"10.3324\/haematol.2020.252130"},{"key":"914_CR29","doi-asserted-by":"crossref","first-page":"e33140","DOI":"10.7554\/eLife.33140","volume":"7","author":"J Comenge","year":"2018","unstructured":"Comenge J, Sharkey J, Fragueiro O, Wilm B, Brust M, Murray P, et al. Multimodal cell tracking from systemic administration to tumour growth by combining gold nanorods and reporter genes. Elife. 2018;7:e33140.","journal-title":"Elife"},{"key":"914_CR30","doi-asserted-by":"crossref","first-page":"58728","DOI":"10.18632\/oncotarget.11233","volume":"7","author":"BD Yadav","year":"2016","unstructured":"Yadav BD, Samuels AL, Wells JE, Sutton R, Venn NC, Bendak K, et al. Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia. Oncotarget. 2016;7:58728\u201342.","journal-title":"Oncotarget"},{"key":"914_CR31","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.csbj.2023.01.020","volume":"21","author":"A Nasimian","year":"2023","unstructured":"Nasimian A, Ahmed M, Hedenfalk I, Kazi JU. A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer. Comput Struct Biotechnol J. 2023;21:956\u201364.","journal-title":"Comput Struct Biotechnol J"},{"key":"914_CR32","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.3390\/ijms24043830","volume":"24","author":"A Nasimian","year":"2023","unstructured":"Nasimian A, Al Ashiri L, Ahmed M, Duan H, Zhang X, R\u00f6nnstrand L, et al. A receptor tyrosine kinase inhibitor sensitivity prediction model identifies AXL dependency in leukemia. Int J Mol Sci. 2023;24:3830.","journal-title":"Int J Mol Sci"},{"key":"914_CR33","doi-asserted-by":"crossref","unstructured":"Nasimian A, Younus S, Hammarlund EU, Pienta KJ, R\u00f6nnstrand L, Kazi JU. A Clear, Legible, Explainable, Transparent, and Elucidative (CLETE) Binary Classification Platform for Tabular Data, bioRxiv 2023:2023.2006.2020.545752.","DOI":"10.1101\/2023.06.20.545752"},{"key":"914_CR34","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850\u2013864.e859.","journal-title":"Cancer Cell"},{"key":"914_CR35","volume":"13","author":"J Chen","year":"2022","unstructured":"Chen J, Wang X, Ma A, Wang QE, Liu B, Li L, et al. Deep transfer learning of cancer drug responses by integrating bulk and single-cell RNA-seq data. Nat Commun. 2022;13:6494.","journal-title":"Nat Commun"},{"key":"914_CR36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41586-018-0436-0","volume":"562","author":"TB Alexander","year":"2018","unstructured":"Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature. 2018;562:373\u20139.","journal-title":"Nature"},{"key":"914_CR37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166:740\u201354.","journal-title":"Cell"},{"key":"914_CR38","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1801-0","volume":"10","author":"F Seyfried","year":"2019","unstructured":"Seyfried F, Demir S, Horl RL, Stirnweiss FU, Ryan J, Scheffold A, et al. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death Dis. 2019;10:571.","journal-title":"Cell Death Dis"},{"key":"914_CR39","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41408-020-0320-7","volume":"10","author":"C Bonolo de Campos","year":"2020","unstructured":"Bonolo de Campos C, Meurice N, Petit JL, Polito AN, Zhu YX, Wang P, et al. \u201cDirect to Drug\u201d screening as a precision medicine tool in multiple myeloma. Blood Cancer J. 2020;10:54.","journal-title":"Blood Cancer J"},{"key":"914_CR40","volume":"6","author":"CF Tsai","year":"2015","unstructured":"Tsai CF, Wang YT, Yen HY, Tsou CC, Ku WC, Lin PY, et al. Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun. 2015;6:6622.","journal-title":"Nat Commun"},{"key":"914_CR41","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.celrep.2014.07.036","volume":"8","author":"K Sharma","year":"2014","unstructured":"Sharma K, D\u2019Souza RC, Tyanova S, Schaab C, Wisniewski JR, Cox J, et al. Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser\/Thr-based signaling. Cell Rep. 2014;8:1583\u201394.","journal-title":"Cell Rep"},{"key":"914_CR42","doi-asserted-by":"crossref","first-page":"M110 004457","DOI":"10.1074\/mcp.M110.004457","volume":"10","author":"A Santamaria","year":"2011","unstructured":"Santamaria A, Wang B, Elowe S, Malik R, Zhang F, Bauer M, et al. The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteom. 2011;10:M110 004457.","journal-title":"Mol Cell Proteom"},{"key":"914_CR43","doi-asserted-by":"crossref","first-page":"rs5","DOI":"10.1126\/scisignal.2001497","volume":"4","author":"AN Kettenbach","year":"2011","unstructured":"Kettenbach AN, Schweppe DK, Faherty BK, Pechenick D, Pletnev AA, Gerber SA. Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal. 2011;4:rs5.","journal-title":"Sci Signal"},{"key":"914_CR44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.12717\/DR.2014.18.1.065","volume":"18","author":"SY Lee","year":"2014","unstructured":"Lee SY, Jang C, Lee KA. Polo-like kinases (plks), a key regulator of cell cycle and new potential target for cancer therapy. Dev Reprod. 2014;18:65\u201371.","journal-title":"Dev Reprod"},{"key":"914_CR45","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/jpet.114.221150","volume":"352","author":"D Rudolph","year":"2015","unstructured":"Rudolph D, Impagnatiello MA, Blaukopf C, Sommer C, Gerlich DW, Roth M, et al. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia. J Pharm Exp Ther. 2015;352:579\u201389.","journal-title":"J Pharm Exp Ther"},{"key":"914_CR46","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1172\/JCI122533","volume":"128","author":"Y Ren","year":"2018","unstructured":"Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, et al. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Invest. 2018;128:5517\u201330.","journal-title":"J Clin Invest"},{"key":"914_CR47","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1007\/s00018-020-03702-9","volume":"78","author":"F Meng","year":"2021","unstructured":"Meng F, Sun N, Liu D, Jia J, Xiao J, Dai H. BCL2L13: physiological and pathological meanings. Cell Mol Life Sci. 2021;78:2419\u201328.","journal-title":"Cell Mol Life Sci"},{"key":"914_CR48","doi-asserted-by":"crossref","unstructured":"Cojocari D, Smith BN, Purkal JJ, Arrate MP, Huska JD, Xiao Y et al. Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia. Haematologica. 2022;107:825\u201335.","DOI":"10.3324\/haematol.2020.272609"},{"key":"914_CR49","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","volume":"26","author":"S Jin","year":"2020","unstructured":"Jin S, Cojocari D, Purkal JJ, Popovic R, Talaty NN, Xiao Y, et al. 5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. Clin Cancer Res. 2020;26:3371\u201383.","journal-title":"Clin Cancer Res"},{"key":"914_CR50","doi-asserted-by":"crossref","unstructured":"Garcia-Aranda M, Perez-Ruiz E, Redondo M. Bcl-2 inhibition to overcome resistance to chemo- and immunotherapy. Int J Mol Sci. 2018;19:3950.","DOI":"10.3390\/ijms19123950"},{"key":"914_CR51","doi-asserted-by":"crossref","unstructured":"Shah K, Al Ashiri L, Nasimian A, Ahmed M, Kazi JU. Venetoclax-resistant T-ALL cells display distinct cancer stem cell signatures and enrichment of cytokine signaling. Int J Mol Sci. 2023;24:5004.","DOI":"10.3390\/ijms24055004"},{"key":"914_CR52","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang H, Nakauchi Y, Kohnke T, Stafford M, Bottomly D, Thomas R, et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020;1:826\u201339.","journal-title":"Nat Cancer"},{"key":"914_CR53","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Glytsou C, Zhou H, Narang S, Reyna DE, Lopez A, et al. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov. 2019;9:890\u2013909.","journal-title":"Cancer Discov"},{"key":"914_CR54","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","volume":"9","author":"T Nechiporuk","year":"2019","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D\u2019Alessandro A, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in aml cells. Cancer Discov. 2019;9:910\u201325.","journal-title":"Cancer Discov"},{"key":"914_CR55","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","volume":"32","author":"R Pan","year":"2017","unstructured":"Pan R, Ruvolo V, Mu H, Leverson JD, Nichols G, Reed JC, et al. Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy. Cancer Cell. 2017;32:748\u2013760.e746.","journal-title":"Cancer Cell"},{"key":"914_CR56","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","volume":"24","author":"LV Pham","year":"2018","unstructured":"Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, et al. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin Cancer Res. 2018;24:3967\u201380.","journal-title":"Clin Cancer Res"},{"key":"914_CR57","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Guieze","year":"2019","unstructured":"Guieze R, Liu VM, Rosebrock D, Jourdain AA, Hernandez-Sanchez M, Martinez Zurita A, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36:369\u2013384.e313.","journal-title":"Cancer Cell"},{"key":"914_CR58","doi-asserted-by":"crossref","first-page":"37942","DOI":"10.18632\/oncotarget.16290","volume":"8","author":"S Kumar","year":"2017","unstructured":"Kumar S, Sharma G, Chakraborty C, Sharma AR, Kim J. Regulatory functional territory of PLK-1 and their substrates beyond mitosis. Oncotarget. 2017;8:37942\u201362.","journal-title":"Oncotarget"},{"key":"914_CR59","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3324\/haematol.2013.084434","volume":"98","author":"SA Hartsink-Segers","year":"2013","unstructured":"Hartsink-Segers SA, Exalto C, Allen M, Williamson D, Clifford SC, Horstmann M, et al. Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells. Haematologica. 2013;98:1539\u201346.","journal-title":"Haematologica"},{"key":"914_CR60","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/ncb1767","volume":"10","author":"Z Fu","year":"2008","unstructured":"Fu Z, Malureanu L, Huang J, Wang W, Li H, van Deursen JM, et al. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol. 2008;10:1076\u201382.","journal-title":"Nat Cell Biol"},{"key":"914_CR61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69338-8","volume":"10","author":"L Gheghiani","year":"2020","unstructured":"Gheghiani L, Shang S, Fu Z. Targeting the PLK1-FOXO1 pathway as a novel therapeutic approach for treating advanced prostate cancer. Sci Rep. 2020;10:12327.","journal-title":"Sci Rep"},{"key":"914_CR62","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.15190\/d.2014.8","volume":"2","author":"O Bucur","year":"2014","unstructured":"Bucur O, Stancu AL, Muraru MS, Melet A, Petrescu SM, Khosravi-Far R. PLK1 is a binding partner and a negative regulator of FOXO3 tumor suppressor. Discoveries. 2014;2:e16.","journal-title":"Discoveries"},{"key":"914_CR63","doi-asserted-by":"crossref","first-page":"e86629","DOI":"10.1371\/journal.pone.0086629","volume":"9","author":"T Moriishi","year":"2014","unstructured":"Moriishi T, Kawai Y, Komori H, Rokutanda S, Eguchi Y, Tsujimoto Y, et al. Bcl2 deficiency activates FoxO through Akt inactivation and accelerates osteoblast differentiation. PLoS One. 2014;9:e86629.","journal-title":"PLoS One"},{"key":"914_CR64","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/sj.cdd.4402017","volume":"14","author":"P Obexer","year":"2007","unstructured":"Obexer P, Geiger K, Ambros PF, Meister B, Ausserlechner MJ. FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ. 2007;14:534\u201347.","journal-title":"Cell Death Differ"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00914-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00914-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00914-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T15:03:15Z","timestamp":1700492595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00914-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["914"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00914-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"3 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}